• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight

cafead

Administrator
Staff member
  • cafead   May 02, 2024 at 10:32: PM
via Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership worth up to $3 billion in biobucks.

article source
 

<